RxSight

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RxSight posts stellar Q4 results, eyes strong growth in 2023

RxSight's Q4 2022 performance reflects robust revenue growth, improved gross margin, and strategic financial management. The company's focus on expanding LDD installations and LAL sales sets a positive trajectory for future growth.
While challenges such as net losses and operating expenses persist, RxSight's strong cash position and revenue guidance for 2023 indicate resilience and potential for sustained growth. Leveraging opportunities in market expansion and product innovation will be key for RxSight's future success.

RxSight reports stellar Q1 revenue growth, eyes profitability challenges

RxSight demonstrated robust revenue growth and a strong cash position in Q1 2023, while facing challenges with profitability and escalating operating expenses. The company's increased revenue guidance and positive market feedback present opportunities for future growth through product adoption and market expansion.

RxSight reports stellar Q2 results, raises guidance amid strategic focus

RxSight's Q2 2023 performance reflects robust revenue growth and margin improvement, supported by strong LAL sales. While challenges like net losses persist, the company's strategic focus on technology and market growth presents promising opportunities for future success.

RxSight reports stellar Q3 results, eyes profitability and product expansion

RxSight's Q3 performance reflects robust revenue growth, driven by strong LAL sales and operational efficiency improvements, positioning the company for future success.
With a focus on innovation and product efficacy, RxSight's strategic strengths lie in their ability to meet market demand and drive revenue through expanded offerings.
While challenges in managing expenses and sustaining growth persist, RxSight's financial strength and market opportunities signal a promising outlook for profitability and value creation.

RxSight reports strong revenue growth driven by LAL sales

RxSight's Q4 2023 performance showcased robust revenue growth driven by LAL sales, despite increased operating expenses and a net loss.
The company's strong cash position, debt-free status, and focus on innovation position it well for future revenue growth and market expansion.
Challenges include managing expenses, navigating complex international markets, and optimizing product mix for sustained profitability.
Opportunities lie in European market expansion, investor engagement, and leveraging technology to drive adoption and revenue growth.

RxSight reports robust Q1 revenue growth, faces expense challenges

RxSight's Q1 2024 performance reflects strong revenue growth and improved gross margin, yet challenges persist with increasing expenses and net loss.
The company's focus on LAL technology, guidance increase, and market expansion efforts present opportunities for future growth and market penetration.
To address challenges, RxSight needs to balance cost management with innovation and capitalize on opportunities in adoption trends and international markets.

RxSight reports robust Q2 earnings, eyes international expansion for growth

RxSight's Q2 performance reflects strong revenue growth, improved margins, and strategic investments in growth areas.
While facing rising expenses, RxSight's focus on premium products, international expansion, and innovation positions it for future success.
Challenges in cost management and market dynamics require careful navigation, but opportunities in product expansion and market penetration are promising.
Overall, RxSight's financial outlook remains positive, supported by a strong cash position and a clear growth strategy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

ALISO VIEJO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report First Quarter Financial Results on May 9, 2023

ALISO VIEJO, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that its Light Adjustable Lens™ system will be the subject of multiple surgeon presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) being held at the San Diego Convention Center on May 5-8, 2023.

Multiple Surgeon Presentations to Highlight RxSight® Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy

ALISO VIEJO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Needham Healthcare Conference.

RxSight, Inc. to Present at the Needham Healthcare Conference

CymaBay Therapeutics

Remitly Global

United Wholesale Mortgage

CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.

4 Best Breakout Stocks to Buy Now for Superlative Returns

RxSight's innovative product, the Light Adjustable Lens, was launched in 2020 and managed to capture a 5% market share by late 2022. The market is expected to double in five years and international expansion is another significant long-term opportunity.

RxSight: Disrupting The Premium Intraocular Lens Market

The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%

RxSight, Inc. (NASDAQ:RXST ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Alex Huang – Investor Relations Ron Kurtz – President and Chief Executive Officer Shelley Thunen – Chief Financial Officer Conference Call Participants Craig Bijou – Bank of America Robbie Marcus – JPMorgan Ryan Zimmerman – BTIG David Saxon – Needham Operator Good day and thank you for standing by. Welcome to the RxSight Fourth Quarter Earnings Conference Call.

RxSight, Inc. (RXST) Q4 2022 Earnings Call Transcript

ALISO VIEJO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2022.

RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

ALISO VIEJO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Oppenheimer Healthcare Conference.

RxSight, Inc. to Present at the Oppenheimer Healthcare Conference

ALISO VIEJO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and fiscal year 2022 after the market close on Monday, March 6, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 6, 2023

ALISO VIEJO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc. (“RxSight®”), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that, in connection with its previously announced public offering of common stock (the “Offering”), the underwriters exercised in full their option to purchase an additional 600,000 shares of RxSight's common stock at a public offering price of $12.50 per share.

RxSight, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of its Public Offering of Common Stock

ALISO VIEJO, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2022.

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results

Here is how RxSight, Inc. (RXST) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year?

The consensus price target hints at a 42.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does RxSight, Inc. (RXST) Have the Potential to Rally 43% as Wall Street Analysts Expect?

The mean of analysts' price targets for RxSight, Inc. (RXST) points to a 45% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 45% Upside in RxSight, Inc. (RXST): Here's What You Should Know

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 12.86% and 19.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates

RxSight, Inc. (NASDAQ:RXST ) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Alex Huang - Associate Director of Investor Relations Ron Kurtz - President and Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants David Saxon - Needham and Company Ryan Zimmerman - BTIG Operator Hello and thank you for standing by. Welcome to the RxSight Third Quarter 2022 Earnings Conference Call.

RxSight, Inc. (RXST) Q3 2022 Earnings Call Transcript

RxSight, Inc. (RXST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RxSight, Inc. (RXST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ALISO VIEJO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report Third Quarter 2022 Financial Results on November 7, 2022

RxSight, Inc. (NASDAQ:RXST ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Alex Huang - Investor Relations Ron Kurtz - President and Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - JP Morgan Operator Good day. And welcome to RxSight Second Quarter 2022 Earnings Conference Call.

RxSight, Inc. (RXST) CEO Ron Kurtz on Q2 2022 Results - Earnings Call Transcript

ALISO VIEJO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it has filed a $200 million shelf registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC").  Once declared effective by the SEC, the shelf registration statement would permit the Company to sell, from time to time, up to $200 million in aggregate value of its common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.

RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Market Equity Offering Program

ALISO VIEJO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2022.

RxSight, Inc. Reports Second Quarter 2022 Financial Results

ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 after the market close on Monday, August 8, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report Second Quarter 2022 Financial Results on August 8, 2022

RxSight, Inc. (NASDAQ:RXST ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Ron Kurtz - President and Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG David Saxon - Needham Company Operator Good day, ladies and gentlemen and welcome to the RxSight, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Philip Taylor.

News for RxSight Stock (RXST)